As well, the ability of nanocarriers to disperse in confined tissues and for nanomedicine to target breast cancer cells overexpressing HER2 and target TNBC and breast cancer stem cells (BCSCs) have been envisioned. This evidence concerns the gene ERBB2 and breast cancer.